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Novel GlioblastomaMarkers with Diagnostic and PrognosticValue
Identified throughTranscriptomeAnalysis
Sreekanth P. Reddy,1Ramona Britto,2 KatyayniVinnakota,1HebbarAparna,1Hari Kishore Sreepathi,3
BalaramThota,5 Arpana Kumari,2 B.M. Shilpa,5 M.Vrinda,5 Srikantha Umesh,5 Cini Samuel,4
Mitesh Shetty,4 AshwaniTandon,5 Paritosh Pandey,5 Sridevi Hegde,4 A.S. Hegde,6
Anandh Balasubramaniam,5 B.A. Chandramouli,5 Vani Santosh,5 Paturu Kondaiah,1
Kumaravel Somasundaram,2 andM.R. Satyanarayana Rao3,7
Abstract Purpose: Current methods of classification of astrocytoma based on histopathologic methods
are often subjective and less accurate. Althoughpatients with glioblastomahave graveprognosis,
significant variability in patient outcome is observed. Therefore, the aim of this study was to
identify glioblastoma diagnostic and prognostic markers throughmicroarray analysis.
Experimental Design:We carried out transcriptome analysis of 25 diffusely infiltrating astro-
cytoma samples [WHO grade IIdiffuse astrocytoma, grade IIIanaplastic astrocytoma, and
grade IVglioblastoma (GBM)] using cDNA microarrays containing 18,981genes. Several of
the markers identified were also validated by real-time reverse transcription quantitative PCR and
immunohistochemical analysis on an independent set of tumor samples (n = 100). Survival anal-
ysis was carried out for two markers on another independent set of retrospective cases (n = 51).
Results:We identified several differentially regulated grade-specific genes. Independent
validation by real-time reverse transcription quantitative PCR analysis found growth arrest and
DNA-damage ^ inducible a (GADD45a) and follistatin-like1 (FSTL1) to be up-regulated inmost
GBMs (both primary and secondary), whereas superoxide dismutase 2 and adipocyte enhancer
binding protein 1were up-regulated in the majority of primary GBM. Further, identification of
the grade-specific expression of GADD45a and FSTL1by immunohistochemical staining rein-
forced our findings. Analysis of retrospective GBM cases with known survival data revealed
that cytoplasmic overexpression of GADD45a conferred better survival while the coexpression
of FSTL1with p53 was associated with poor survival.
Conclusions: Our study reveals that GADD45a and FSTLI are GBM-specific whereas super-
oxide dismutase 2 and adipocyte enhancer binding protein1are primary GBM-specific diagnostic
markers.Whereas GADD45a overexpression confers a favorable prognosis, FSTL1 overexpres-
sion is a hallmark of poor prognosis in GBM patients.
Diffuse-infiltrating astrocytomas include the following enti-
ties: (a) diffuse astrocytoma (DA; WHO grade II), (b) anaplastic
astrocytoma (AA; WHO grade III), and (c) glioblastoma (GBM;
WHO grade IV). AA and GBMs constitute malignant astrocy-
tomas and are the most common intrinsic central nervous sys-
tem neoplasms (1). The prognosis of patients with these tumors
is dismal, and GBM, which is the most malignant phenotypic
variant, has a mean survival of 10 to 12 months (2). Currently
available treatment options are multimodal, which include
surgery, radiotherapy, and chemotherapy. However, these have
been shown to improve survival onlymarginally inGBMpatients.
The development of GBM has been described to occur
through at least two genetic pathways resulting in the
formation of primary and secondary GBMs (3). Primary GBM
represents the most frequently presenting variant occurring
de novo without an evidence of a less malignant precursor.
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Patients under this category are commonly of older age and
have a high rate of epidermal growth factor receptor (EGFR) gene
amplification, p16 INK4A deletion, mutations in PTEN gene,
and MDM2 amplification. In contrast, secondary GBM occurs
after a preceding diagnosis of lower-grade astrocytomas.
Mutations in the p53 gene, RB alterations, and PDGFR
amplification and overexpression are thought to be more
common in the development of secondary GBM (3, 4). In spite
of these genetic differences, it remains uncertain whether these
subtypes differ significantly with respect to prognosis (5).
Microarray expression profiling of glioma allows simulta-
neous analysis of thousands of genes and is likely to identify
molecular markers associated with tumor grade, progression,
and patient survival (6, 7). In a previous study, we reported
differential gene expression between low-grade astrocytoma
and GBM, and proposed a role for notch pathway in
progressive astrocytoma development (8). The purpose of this
study was to identify genes that are differentially regulated
during the development of malignant astrocytomas, in partic-
ular, GBM. Through cDNA microarray experiments, we have
identified several distinct gene categories of transcripts overex-
pressed in different grades of astrocytoma. In addition, we have
validated the identified genes that characterize GBM, in
particular primary GBM. The prognostic value of some of the
markers is also studied.
Materials andMethods
Tumor samples. Tumor samples were collected from patients who
were operated on at Manipal Hospital, Sri Satya Sai Institute of Higher
Medical Sciences, and National Institute of Mental Health and
Neurosciences, Bangalore, India. Normal brain tissue samples (anterior
temporal lobe) obtained during surgery for intractable epilepsy
were used as control samples. A total of 131 samples of different
grades of astrocytomas and normal brain samples were used in this
study. For microarray hybridization, a set of 25 samples of diffusely
infiltrating astrocytomas comprising 4 DAs, 5 AAs, 16 GBMs (6 second-
ary and 10 primary), and 5 normal controls were used. For subsequent
real-time reverse transcription-PCR validation of selected genes, we used
an independent set of 91 samples of diffusely infiltrating astrocytomas
comprising 5 DAs, 31 AAs, 55 GBMs (20 secondary and 35 primary),
and normal brain tissue from another set of nine controls. Tissues were
bisected, and one half was snap-frozen in liquid nitrogen and stored
at -80jC until RNA isolation. The other half was fixed in formalin and
processed for paraffin sections. These were used for histopathologic
grading of astrocytoma and immunohistochemistry.
RNA isolation, cDNA labeling, and microarray hybridization. Total
RNA was extracted from the frozen tissue by using the TRI reagent
(Sigma). The RNA samples were quantified by measuring the
absorbance using a spectrophotometer and visualized on a MOPS-
formaldehyde gel for quality assurance. cDNA synthesis and labeling of
total RNA were done using the Micromax direct labeling kit (Perkin-
Elmer Life Sciences, Inc.). RNA derived from normal brain tissue was
labeled with cyanine 3 dUTP, whereas that of tumor was labeled with
cyanine 5 dUTP. Twenty micrograms of total RNA were used for each
labeling reaction. The quality of cDNA labeling was monitored by
separating small amounts of cyanine 3– and cyanine 5–labeled cDNA
in an agarose gel made on a microscopic slide and scanning the gel
using the laser scanner LSIV (Genomic Solutions). Cyanine 3– and
cyanine 5–labeled cDNAs were added to 100 AL of 1 hybridization
buffer (Ultrahyb, Sigma), incubated at 75jC for 5 min before adding to
the 19 k arrays (University Health Network). Hybridization was carried
out in a GeneTAC Hyb Station (Genomic Solutions) at 65jC for 4 h,
60jC for 4 h, and 55jC for 10 h. The slides were washed using medium
stringency, high stringency, and postwash buffers (Genomic Solutions)
for five times each; dried; and scanned using the Scanarray Express
(Perkin-Elmer).
Microarray image and data analysis. Image analysis was carried out
with the GeneTAC Analyzer software, version 3.3 (Genomic Solutions),
and filtering and assembling of data were done using MS Excel and MS
Access. To begin with, the image was visually inspected and spots of
questionable quality were flagged and eliminated from further
consideration. In the next step, spots having a signal-to-noise ratio
<1.5 in both channels and total intensity values below a threshold
value were excluded. We first computed arithmetic mean and SD for
background subtracted total intensities of all negative control spots
(3 SSC) on the slide and then computed threshold value as arith-
metic mean plus 2 SDs. If the coefficient of variation of expression
ratios of duplicate spots of a given gene is >20%, then the gene was
excluded from further analysis. Within-array normalization (Lowess-tip
wise) and across-array normalization were done using MIDAS software
(9). The cyanine 5/cyanine 3 normalized expression ratio was
determined for each spot and the values from the duplicate spots
within each array were averaged and log 2 transformed. All the
subsequent analyses were done using log 2–transformed data. We have
analyzed four grade 2, five grade 3, six secondary GBM, and ten primary
GBM samples by microarray hybridization. The genes having values in
at least 50% of the samples in each group were considered for further
analysis. To find the significantly differentially regulated genes between
normal brain and astrocytoma, and between the groups of astrocytoma,
data were analyzed by Significance Analysis of Microarrays (SAM; ref.
10). SAM one-class option with estimated false discovery rate (median)
<5% and fold-change cutoff of 3 was used to identify significantly dif-
ferentially regulated genes between normal and tumor. SAM two-class
option with estimated false discovery rate (median) <5% and fold-
change cutoff of 1.5 was used to identify significantly differentially
regulated genes between different groups of glioma. SAM-identified
genes were subjected to hierarchical cluster analysis using TMEV
software to see the substructure of the data (9).
Real-time quantitative reverse transcription-PCR. The relative quan-
tification of the expression levels of selected genes was carried out using
a two-step strategy: In the first step, cDNA was generated from RNA
derived from different tissue samples using a cDNA archive kit (ABI
PRISM); subsequently, real-time quantitative PCR was carried out in an
ABI PRISM 7900 (Applied Biosystems) sequence detection system with
the cDNA as template using gene-specific primer sets and a Dynamo
kit containing SYBR green dye (Finnzyme). All measurements were
made in triplicate. The genes GARS (glycyl-tRNA synthetase), AGPAT1
(1-acylglycerol-3-phosphate O-acyltransferase 1), ATP5G1 [ATP syn-
thase, H+ transporting, mitochondrial F0 complex, subunit C1 (subunit
9)], and RPL35A (ribosomal protein L35a) were used as internal
controls because their expression levels were found to be unaltered in
the array experiments. Normal brain tissue samples from nine different
epilepsy patients were used as reference. DCT method was used for
the calculation of ratios. An increase or decrease in gene expression
by 4-fold (log 2 ratio = 2) or more over its mean expression in reference
samples was chosen as threshold to calculate the percentage of
regulated samples. Statistical significance was tested by Mann-
Whitney test using GraphPad PRISM software. Sequences of reverse
transcription-PCR primers and conditions used will be provided on
request.
Histopathology and immunohistochemistry. Histologic sections of
normal brain and tumor tissues were examined by light microscopy
using H&E preparation. Tumor sections of diffusely infiltrating astro-
cytomas were graded using the WHO grading scheme (11). Paraffin
sections (4 Am) from the tumor tissue and control samples were col-
lected on silane-coated slides for immunohistochemistry. Newly recog-
nized markers, namely growth arrest and DNA-damage– inducible a
(GADD45a) and follistatin-like 1 (FSTL1), were validated. The primary
antibodies were GADD45a (rabbit polyclonal, 1:50 dilution) and
FSTL1 (rabbit polyclonal, 1:100 dilution). GADD45a antibody (clone
Markers for GBM
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C-20) was obtained from Santa Cruz Biotechnology. Rabbit polyclonal
antibody against purified GST-FSTL1 protein was made using standard
immunization protocol. Microwave antigen retrieval was done at
400 W for 18 min in 10 mmol/L citrate buffer (pH 6.0). The antibodies
used mainly for the purpose of subclassifying GBM cases were p53
(monoclonal: DO-7, Biogenix, diluted to 1:200) and EGFR (monoclo-
nal: E-30, Biogenix, diluted to 1:50). For p53, antigen retrieval was done
by heat treatment of the deparaffinized sections in a microwave oven
for 25 to 35 min at 700 W in citrate buffer (10 mmol/L, pH 6.0). For
EGFR staining, the sections were pretreated with Tris-EDTA (pH 9.0) at
600 W for 30 min. All sections were further treated with methanol and
5% hydrogen peroxide to block endogenous peroxidase followed by
washes with PBS buffer (pH 7.6). Skimmed milk powder (5%) was used
to block background staining for 45 min. The sections were incubated
with the primary antibody overnight at 4jC. This was followed by incu-
bation with supersensitive nonbiotin horseradish peroxidase detection
Fig. 1. Two-way hierarchical clustering of
SAM-identified grade-specific genes.
Normalized, log 2^ transformed expression
ratios of SAM-identified differentially
regulated genes were subjected to two-way
hierarchical clustering usingTMEV software
to see if gene sets can cluster samples of
different grades separately. A dual-color
codewasused,with redandgreenindicating
up- and down-regulation, respectively, in
the particular glioma sample comparedwith
normal brain tissue. A, differentially
regulated genes between DA and AA.
Twenty-six genes were up-regulated in DAs
as against AAs and 7 genes were
up-regulated in AA as against DA. B,
differentially regulated genes between
DA/AA and GBM. Forty-one genes were
up-regulated in DAs and AAs as against
GBMs, and 37 genes were up-regulated
in GBMs as against DAs and AAs.C,
differentially regulated genes between
secondary GBMand primary GBM.
Thirty-nine genes were up-regulated in
primary GBMin comparisonwith secondary
GBMand 30 genes were up-regulated in
secondary GBMin comparisonwith primary
GBM.D, differentially regulated genes
between progressive astrocytoma and
primary GBM.Twenty genes were
up-regulated in progressive astrocytoma
(DA, AA, and secondary GBM) as
against primary GBMand 45 genes were
up-regulated in primary GBMs
as against progressive astrocytoma.
Imaging, Diagnosis, Prognosis
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system (QD440-XAK, Biogenex). 3,3¶-Diaminobenzidine (Sigma) was
used as chromogenic substrate.
Brain tumor samples previously characterized for overexpression of
p53 and EGFR were used as positive controls. p53 and EGFR
immunoreactivity was considered positive when >20% of tumor cells
stained positively (nuclear and membrane cytoplasmic labeling,
respectively). GBMs were classified as primary and secondary, taking
into consideration the clinical profile of patients, expression of EGFR,
and p53 (5). The mean age of patients with primary GBM was 50.6 y
and the mean duration of symptoms was 2.7 mo. Uniform staining for
EGFR was evident in all cases and five revealed additional p53
expression. Among secondary GBMs, the mean age of the patients
was 33.8 y and the mean duration of symptoms was 5.3 mo. p53
immunoreactivity was uniformly evident in all cases and two revealed
additional EGFR overexpression.
The staining pattern was diffuse cytoplasmic with both GADD45a
and FSTL1 antibodies. A staining intensity of 3+ in the tumor cell
cytoplasm and a cutoff value of 20% tumor cell positivity were
considered to label the tumor as positive. GBM tumor samples showing
significantly high expression of mRNA levels by reverse transcription-
PCR was taken as positive control. A negative control slide in which
the primary antibody was excluded was incorporated with each batch
of slides.
Immunohistochemistry on archival samples of GBM to assess the
survival value of GADD45 and FSTLI. To analyze the survival value of
GADD45a and FSTL1, we subjected a different set of 51 retrospective
GBM cases, where follow-up was available, for expression of these two
markers along with p53 and EGFR by immunohistochemical analysis.
Case records of GBM patients operated on in the year 2002 were
retrospectively analyzed and follow-up data were collected. Postal
questionnaires were sent to all these patients, requesting their present
functional status and date of expiry, when appropriate. Of these,
51 cases of adult supratentorial, lobar GBM patients who underwent an
open surgery and had at least one postoperative follow-up were selected
and shown to be representative of the total 96 cases of GBM operated
on in that year by independent samples t test.
The mean age of the patients in the retrospective group analyzed was
45.3 y (18-80 y) and their mean Karnofsky performance status at
presentation was 60.9 (30-90). Of these 51 patients, 35 (68.6%)
underwent near-total/gross-total resection, and a subtotal resection was
achieved in the rest. All the patients were referred for adjuvant therapy.
The median duration of follow-up was 8 mo (1-53 mo). The formalin-
fixed, paraffin-embedded blocks of the 51 cases were retrieved. Fresh
sections (4 Am) were collected on silane-coated slides and immunos-
tained for GADD45a, FSTL1, p53, and EGFR. A cutoff of 20% for
GADD45a and 40% for FSTL1 was considered for statistical analysis.
Statistical analysis. Statistical analysis was done using SPSS 10.0
software. For univariate analysis, Kaplan-Meier survival curves with log-
rank statistical correlations were used. Multivariate analysis was done
using the Cox proportional hazard model (Enter method), with age,
operative extent of resection, Karnofsky performance status at presen-
tation, radiotherapy, p53 expression, and EGFR overexpression as the
constant clinical covariants, and adding the immunohistochemical
marker as appropriate.
Results
Transcriptome analysis of astrocytomas. We analyzed the
expression profile of 18,981 human genes using 19 k cDNA
microarrays for 25 samples of diffusely infiltrating astrocytoma
comprising 4 DA (grade II), 5 AA (grade III), and 16 GBM
(grade IV; 6 secondary and 10 primary). Of these, only 14,929
genes for which data were available for >50% of the samples
within each grade were considered for subsequent analysis. The
data obtained from image analysis were filtered, normalized,
and log 2 transformed before being used for further studies.
To identify the significantly differentially regulated genes
between normal and astrocytoma samples as well as between
different grades of astrocytoma, data were subjected to SAM
using the one-class and two-class options as required. To obtain
a visual appreciation of the sets of differentially regulated
genes between different groups and to verify whether identified
gene sets can differentiate samples into different groups, the
data obtained from SAMwere subjected to an unsupervised, two-
way, average-linkage hierarchical cluster analysis with Euclidean
distance as similarity metric using the TMEV software.
SAM analysis identifies grade-specific genes. Examination of
14,929 gene data sets derived from 25 astrocytoma samples
through SAM analysis found 385 to be up-regulated and
911 genes to be down-regulated in all groups of astrocytoma in
comparison with normal brain sample, thus confirming the fact
that astrocytoma development and progression are associated
with altered gene expression profile. DAs (grade II) are diffusely
infiltrating low-grade astrocytoma that progress over to
malignant grade III anaplastic astrocytoma and grade IV GBM
over a period of 5 to 10 years (4, 5, 12). To better under-
stand the gene expression changes during progression from DA
(grade II) to AA (grade III), we compared the data obtained
from four DA and five AA samples through SAM. We found 26
genes to be up-regulated in DA as against AA and 7 genes up-
regulated in AA as against DA (Fig. 1A; Supplementary
Table S1). AAs (grade III) are less malignant than GBMs, with
AA patients having a mean survival of 2 to 3 years in com-
parison with GBM patients whose mean survival is <1 year
(3, 5, 13, 14). To identify the genes that are differentially
regulated between GBM and less malignant grades (DA and
AA), we subjected the data obtained from 9 of the later group
(4 DA and 5 AA) and 16 GBM (10 primary and 6 secondary)
through SAM analysis. We found 41 genes up-regulated in DA
and AA as against GBM and 37 genes up-regulated in GBM as
against DA and AA (Fig. 1B; Supplementary Table S2). The
primary and secondary GBM arise through different genetic
pathways, suggesting the existence of differences in the
expression profile between these two classes. Accordingly, to
identify genes that are differentially regulated between primary
and secondary GBM, we subjected the data obtained from 10
primary GBM and 6 secondary GBM samples through SAM
analysis. We found 39 genes up-regulated in primary GBM in
comparison with secondary GBM and 30 genes up-regulated in
secondary GBM in comparison with primary GBM (Fig. 1C;
Supplementary Table S3). Because secondary GBM progresses
from lower grades (i.e., DA and AA), it is likely that these
tumors share an expression profile with DA and AA as against
primary GBM. Thus, to obtain the expression profile specific to
progressive astrocytoma (DA, AA, and secondary GBM) as
against primary GBM (de novo GBM), we compared the data
obtained from 15 samples belonging to progressive astrocyto-
ma (4 DA, 5 AA, and 6 secondary GBM) and 10 samples
belonging to primary GBM through SAM analysis. We found 20
genes up-regulated in progressive astrocytoma as against
primary GBM and 45 genes up-regulated in primary GBM
as against progressive astrocytoma (Fig. 1D; Supplementary
Table S4).
GADD45a and FSTL1 are GBM-specific markers. Genes that
are specifically up-regulated in GBM samples (see above)
included many novel genes in addition to genes that are
reported by others. We have validated some of the relevant
Markers for GBM
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genes by real-time quantitative reverse transcription-PCR.
In concurrence with previously published reports, additional
validation by real-time quantitative reverse transcription-
PCR confirmed the GBM-specific expression of insulin-like
growth factor binding protein 2 and collagen type-IVa2 (data
not shown).
A novel gene up-regulated in primary GBM is GADD45a
(DDIT1). We found >4-fold up-regulation of GADD45a
transcripts in majority of primary GBM (62.80%; 22 of 35
with a median log 2 ratio of 2.30) and secondary GBM samples
(50.00%; 10 of 20 with a median log 2 ratio of 2.35) as against
22.50% (7 of 31 with a median log 2 ratio of 0.20) among AA
and 20.00% (1 of 5 with a median log 2 ratio of 0.80) among
DA samples (P = 0.0106; Fig. 2A). We also analyzed the
expression pattern of GADD45a by immunohistochemical
staining (Fig. 3). Among primary and secondary GBM samples
tested, 58.0% (7 of 12) and 50.0% (3 of 6) of them,
respectively, showed strong positive cytoplasmic staining for
GADD45a. The percentage positivity for GADD45a staining
in AA (grade 3) and DA (grade 2) was found to be 14.0%
(1 of 7) and 0.0% (0 of 3), respectively. The average percent
positive tumor cells was found to be higher among pri-
mary GBM samples (30.0%), followed by 25.0% and 20.0%
among secondary GBM and AA, respectively. Analysis of five
normal brain samples showed glial cells to be negative for
GADD45a staining.
Another interesting gene up-regulated in majority of GBM
cases was FSTL1 , which encodes a protein with similarity to
follistatin, an activin-binding protein. The levels of FSTL1
transcripts were found to be increased >4-fold in majority of
primary GBM (80.00%; 28 of 35 with a median log 2 ratio
of 2.80) and secondary GBM samples (55.00%; 11 of 20 with a
median log 2 ratio of 2.0) as against 12.90% (4 of 31 with a
median log 2 ratio of 0.8) and 0.0% (0 of 5 with a median log 2
ratio of 0.8) among AA and DA samples, respectively, with
P value reaching significance (P = 0.0042; Fig. 2B). Immuno-
histochemical analysis revealed that 85.0% (18 of 21) and
86.0% (9 of 15) of primary and secondary GBM, respectively,
are positive for FSTL1 protein staining (Fig. 4). As expected,
reduced positivity was found among AA (30.0%; 3 of 10) and
DA (0.0%; 0 of 10). Staining of normal brain revealed glial cells
to be negative for FSTL1 staining. The average percent positive
tumor cells was found to be higher among primary GBM and
secondary GBM (31% and 24%, respectively) as against only
13.0% among AA cases, suggesting that FSTL1 is expressed in
very high levels among GBMs.
Identification of primary GBM-specific genes. Genes that were
up-regulated in primary GBM identified through SAM analysis
included many novel genes. In addition, some of the genes that
have been reported previously by others were found to be vali-
dated as primary GBM-specific genes. These include chitinase
3-like 1 and Ras homologue gene family member C (data not
Fig. 2. Scatter plots of up-regulated genes
in GBMs. Log 2^ transformed gene
expression ratios obtained from real-time
quantitative PCR analysis are plotted for
GADD45a (A) and FSTL1 (B). Each dot
represents data derived fromone sample. For
each sample, fold change in gene expression
is calculated over its mean expression in
normal brain samples. Dotted line represents
the fold change threshold (four-fold log 2
ratio = 2) used to calculate the percentage of
regulated samples.
Imaging, Diagnosis, Prognosis
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shown). For some of the novel genes, we have carried out real-
time quantitative PCR and immunohistochemical validation
wherever antibody was available on an independent set of
tumor samples.
Manganese superoxide dismutase (SOD2), located in the
mitochondria, was up-regulated >4-fold in majority of primary
GBM (71.4%; 25 of 35 with a median log 2 ratio of 2.70) in
comparison with secondary GBM (20.00%; 4 of 20 with a
median log 2 ratio of 0.15), AA (16.10%; 5 of 31 with a median
log 2 ratio of 0.20), and DA (0.0%; 0 of 5 with a median log 2
ratio of 1.20) with a P value of 0.001 (Fig. 5A). Adipocyte
enhancer binding protein 1 (AEBP1) was up-regulated >4-fold
in the majority of primary GBM (57.0%; 20 of 35 with a
median log 2 ratio of 2.4) as against secondary GBM (40.0%;
8 of 20 with a median log 2 ratio of 1.00), AA (12.9%; 4 of 31
with a median log 2 ratio of -1), and DA (20.0%; 1 of 5 with a
median log 2 ratio of 0.8), with a P value of 0.0269 (Fig. 5B).
Survival value of GADD45a and FSTL1. To analyze the
survival value of GADD45a and FSTL1, we subjected a different
set of 51 retrospective GBM cases where follow-up was available
for expression of these markers. In GBM patients, although
the prognostic significance of clinical variables in predicting
survival have been clearly defined, altered protein expression of
the well-known genetic alteration found in these tumors, like
overexpression of p53 and EGFR expression, have individually
failed to give a clear-cut prognostic significance, with con-
founding results in different studies (15–17). Therefore, for the
purpose of multivariate analysis, we immunostained the
sections to study the expression of p53 and EGFR to analyze
the significance of their coexpression with GADD45 and FSTLI
with respect to patient survival.
In univariate analysis, the median survival of the group
positive for GADD45awas 13months compared with 7 months
in the group that was negative (data not shown). However,
this did not reach statistical significance (P = 0.96). Further,
in multivariate analysis, this seemingly favorable effect of
GADD45a positivity was retained, with a trend toward statis-
tical significance (P = 0.051; odds ratio, -3.711; Fig. 6A). These
results indicate that cytoplasmic overexpression of GADD45a in
GBMs probably confers a survival advantage to these patients.
With respect to correlation of expression of FSTL1 with sur-
vival, it independently did not correlate with survival. However,
its coexpression with p53 was associated with a poorer sur-
vival. By univariate analysis, the median survival of the group
Fig. 3. Immunohistochemical validation of
GADD45a overexpression in astrocytoma.
Results of staining for GADD45a were
as follows: sections from normal brain,
negative for staining (A); DA, negative for
staining (B); AA, negative for staining
(C); secondary GBM, positive for
staining (D); and primary GBM, positive
for staining (E).
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that coexpressed p53 and FSTL1 was 8 months, compared
with 13 months in the group that did not coexpress the two
markers (P = 0.04; Fig. 6B). Similarly, by multivariate anal-
ysis, whereas FSTL1 expression by itself did not correlate
with survival, its coexpression with p53 again was associated
with poorer survival (Fig. 6C). These data put together sug-
gest that expression of GADD45a and FSTL1 have prog-
nostic value.
Discussion
Diffusely infiltrating astrocytomas are heterogeneous neo-
plasms and are currently being diagnosed and graded by well-
defined histopathologic criteria (4). GBMs constitute the most
malignant form of this group of astrocytoma. Despite the fact
that several genetic alterations have been described in GBMs,
they have not been very useful in prognostication or for
therapeutic stratification (18). Recently, microarray-based
expression profiling studies have revealed that molecular
subclassification of malignant astrocytoma, particularly GBMs,
could be of prognostic value (6). Therefore, identification of
these molecular subclasses of GBMs could greatly facilitate
prognostication and our ability to develop effective treatment
protocols.
We have used cDNAmicroarray–based expression profiling of
25 diffuse-infiltrating astrocytoma samples belonging to various
grades to identify genes expressed in a grade-specific manner. We
have identified several genes, whose expression is characteristic
to particular grades of astrocytoma. Further, by using real-time
quantitative PCR, we were able to confirm specific expression of
many genes in GBM, particularly primary GBM. Similar to
reported information in the literature, we were able to show
GBM-specific expression of insulin-like growth factor binding
protein 2 and collagen type-IVa2, and primary GBM-specific
expression of chitinase 3-like 1 (CHI3L1/YKL40) and RhoC.
More importantly, we were able to identify four novel markers:
GADD45a and FSTL1 as GBM-specific markers, and SOD2
and AEBP1 as primary GBM-specific markers. The grade-specific
expression of GAD45a and FSTL1 was also shown by immuno-
histochemical staining. In addition, survival analysis revealed
that GADD45a and FSTL1 are prognostic markers as well.
We found GADD45a to be up-regulated in majority of GBM
cases as against DA and AA. GADD45a is a member of a group
of genes whose transcript levels are increased following stressful
Fig. 4. Immunohistochemical validation of
FSTL1overexpression in astrocytoma.
Results of staining for FSTL1were as
follows: sections from normal brain,
negative for staining (A); DA, negative for
staining (B); AA, negative for staining
(C); secondary GBM, positive for staining
(D); and primary GBM, positive for
staining (E).
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growth arrest conditions and treatment with DNA-damaging
agents (19). Under stress conditions like DNA damage,
GADD45a protein is known to induce growth arrest and
apoptosis by activating p38/c-Jun-NH2-kinase pathway via
MTK1/MEKK4 kinase (20). Further, it was found that 13.6%
of invasive ductal carcinomas of the pancreas had mutation in
GADD45a, and the expression of Gadd45a, combined with
that of p53, significantly affected the survival of patients with
resectable invasive ductal carcinomas of the pancreas (21).
Given this information, it was surprising to see the elevated
RNA and protein levels of GADD45a in majority of primary
GBMs compared with normal brain and lower grades of
astrocytoma. However, immunohistochemical analysis revealed
that GADD45a was primarily located in cytoplasm. GADD45a
being a nuclear protein, cytoplasmic sequestration might reflect
a functionally inactive protein. Thus, one would consider
that cytoplasmic localization of GDD45a in GBM might lead
to functionally inactive protein and poor patient survival. In
contrast to this notion, cytoplasmic overexpression seems to
provide survival advantage to the GBM patients as per our
results. One way to explain this paradox is as follows:
GADD45a overexpression in human fibroblast is shown to
cause cell cycle arrest (22). However, there are conflicting
reports that GADD45 proteins induce as well as inhibit
apoptosis under varying conditions (23). Interestingly, it was
found that GADD45 proteins bind to MTK1 and activate its
kinase activity. Further, it was found that expression of
GADD45 genes induces p38/c-Jun-NH2-kinase activation and
apoptosis, which can be partially suppressed by coexpression of
a dominant negative MTK1 mutant (20). There is also a report
suggesting that GADD45 proteins interact with p38 kinase
directly during stress-induced signaling and is believed to play
an ancillary function to GADD45 interactions with MTK1 (24).
This set of data clearly furnish evidence for a function of
GADD45 proteins in cytoplasm as well. It is proposed that the
outcome of GADD45-mediated activation of p38 and c-Jun-
NH2-kinase, resulting in cell cycle arrest, DNA repair and cell
survival, or apoptotic cell death, is determined by the nature of
the stress stimulus, its magnitude, and the levels of GADD45
proteins in cytoplasm to bring out effective interactions.
Although our results indicate that increased expression of
GADD45a levels correlate with GBM, a subgroup of patients
having higher levels of GADD45a protein in tumors had good
prognosis. Perhaps the very high cytoplasmic levels of
GADD45a might reflect an efficient activation of p38/c-Jun-
NH2-kinase pathway leading to apoptosis of the tumor cells,
thus providing survival advantage to these patients.
FSTL1 or follistatin-related protein (FRP), a gene that en-
codes a protein with similarity to follistatin, an activin-binding
protein, is found to be induced four-fold in majority of primary
GBMs in this study. FSTL1 contains an FS module, a follistatin-
like sequence containing 10 conserved cysteine residues and is
Fig. 5. Scatter plots of up-regulated
genes in pGBMs. Log 2^ transformed gene
expression ratios obtained from real-time
quantitative PCR analysis are plotted for
SOD2 (A) and AEBP1 (B). Each dot
represents data derived from one sample.
For each sample, fold change in gene
expression is calculated over its mean
expression in normal brain samples.
Dotted line represents the fold change
threshold (four-fold log 2 ratio = 2) used to
calculate the percentage of regulated
samples.
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thought to be an autoantigen associated with rheumatoid
arthritis (25). FSTL1 was originally identified as TSC-36 (TGFh
stimulated clone 36; ref. 26) and an estrogen-regulated gene
(27). TSC-36 expression has been shown to inhibit growth
of lung cancer cells (28) and proliferation of migration in
vascular smooth muscle cells (29). In contrast to these
observations, FSTL1 has been shown to promote metastasis in
prostate cancer cells (30). FSTL3, a member of a folllistatin-like
family of genes, has been recently shown to promote
proliferation of breast cancer cells (31). However, the actual
role of FSTL1 in human cancers, particularly astrocytomas, is
largely unknown. Interestingly, in addition to GBM-specific
overexpresison, coexpression of FSTL1 with p53 was found to
be associated with poor survival both in univariate and
multivariate analysis.
SOD2, located in the mitochondria, was up-regulated in
primary GBM in comparison with secondary GBM, AA, and DA.
The SOD2 gene encodes an intramitochondrial free radical
scavenging enzyme, which is the first line of defense against
superoxide produced as a byproduct of oxidative phosphory-
lation. This enzyme catalyzes the dismutation of the superoxide
anion to H2O2, which is converted to water by catalases and
peroxidases. SOD2 was initially thought to be a tumor
suppressor protein as its overexpression inhibited cellular
proliferation and reduced levels have been seen in many cancer
cell lines compared with their counterparts (32). However,
many recent reports showed high levels of SOD2 in thyroid
cancer, central nervous system tumors, and acute leukemia, and
also correlated with high metastatic gastric and colorectal
carcinoma (33). Further, it has been shown that increased
metastatic potential of SOD2-overexpressing tumor cell lines
may be attributed to their enhanced matrix metalloproteinase
production (34). In view of the above, perhaps the higher
expression of SOD2 in GBM also contributes to increased
invasive potential of these tumors.
AEBP1 was up-regulated >4-fold in majority of primary GBM
as against secondary GBM, DA, and AA. AEBP1, a transcrip-
tional repressor with carboxypeptidase activity, binds to a
regulatory sequence, adipocyte enhancer 1, located in the
proximal promoter region of the adipose P2 gene, which
encodes the adipocyte fatty acid–binding protein (35). AEBP1
has been shown to interact with the tumor suppressor protein
PTEN and inhibit its function, thus promoting cell prolifera-
tion (36). Further, AEBP1 levels were found to be higher in
proliferative preadipocytes whereas its expression was abol-
ished in terminally differentiated, nonproliferative adipocytes
(37). Thus, overexpression of AEBP1 in primary GBM is likely
to promote proliferation.
Thus, we have identified and validated a set of novel candidate
genes whose expression at the transcript level is associated with
the WHOmalignancy grade of diffusely infiltrating astrocytomas.
We have also identified the prognostic value of some of these
markers. The knowledge about their possible roles in glioma
development is still limited. Therefore, further studies are
required to more precisely characterize the functional significance
of these genes in glioma progression as well as their potential
application for glioma grading and the assessment of prognosis.
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Fig. 6. Survival of patients with GBM. Kaplan-Meier survival estimates for 51GBM
samples are calculated for p53, EGFR1, GADD45a, and FSTL1staining. A, survival
curves for the groups positive and negative for GADD45a, in multivariate analysis.
The cases that were positive for GADD45a (black line) had a better survival than
the cases that were negative (gray line), with a trend toward statistical significance.
B, survival curves for the groups positive and negative for coexpression of p53 and
FSTL-1in univariate analysis.The median survival for the group positive for both
markers was 8 mo (black line) comparedwith13mo for the group negative for both
or either markers (gray line). C, survival curves for the groups positive and negative
for coexpression of p53 and FSTL-1, in multivariate analysis.The group positive for
both markers (black line) had poor survival compared with the group negative for
both or either markers (gray line).
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